Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma (CUE)
:CUE
Holding CUE?
Track your performance easily
CUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $2.93
Previous CloseN/A
Volume91.78K
Average Volume (3M)377.78K
Market Cap
$81.09M
Enterprise Value$15.88M
Total Cash (Recent Filing)$14.98M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 12, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding63,350,327
10 Day Avg. Volume477,708
30 Day Avg. Volume377,783
Standard Deviation0.25
R-Squared0.11
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.51
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue1.62
Enterprise Value/Gross Profit2.89
Enterprise Value/Ebitda-0.40
Forecast
1Y Price Target
$3.00Price Target Upside134.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cue Biopharma News
PremiumCompany Announcements
Cue Biopharma Reports Increased Revenue Amid Ongoing Losses
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCue reported $3.3MM in collaboration revenues, which was higher than the estimated $2.8MM.
Product DevelopmentThe CUE-500 series offers a potential off-the-shelf alternative to CAR-T cell therapies, which could generate significant shareholder value.
Strategic PartnershipsThe partnership with Ono Pharmaceuticals for CUE-401 in the autoimmune space holds significant potential, with Cue retaining 50% of the rights in the U.S. market.
Bears Say
Financial PerformanceR&D expenses were $9.3MM, higher than the estimated $8.1MM, indicating increased spending.
Strategic FocusThe company has deprioritized its oncology programs, which may impact its current focus and resources.
Valuation ImpactThe restructuring led to the elimination of CUE-101 from valuation, resulting in a lower price target for the company.
---
Ownership Overview
0.52% Insiders
4.10% Mutual Funds
0.05% Other Institutional Investors
91.96% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CUE FAQ
What was Cue Biopharma’s price range in the past 12 months?
Cue Biopharma lowest stock price was $0.45 and its highest was $2.93 in the past 12 months.
What is Cue Biopharma’s market cap?
Cue Biopharma’s market cap is $81.09M.
When is Cue Biopharma’s upcoming earnings report date?
Cue Biopharma’s upcoming earnings report date is Mar 12, 2025 which is in 50 days.
How were Cue Biopharma’s earnings last quarter?
Cue Biopharma released its earnings results on Nov 14, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.182 by $0.012.
Is Cue Biopharma overvalued?
According to Wall Street analysts Cue Biopharma’s price is currently Undervalued.
Does Cue Biopharma pay dividends?
Cue Biopharma does not currently pay dividends.
What is Cue Biopharma’s EPS estimate?
Cue Biopharma’s EPS estimate is -0.09.
How many shares outstanding does Cue Biopharma have?
Cue Biopharma has 63,350,327 shares outstanding.
What happened to Cue Biopharma’s price movement after its last earnings report?
Cue Biopharma reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.182. Following the earnings report the stock price went down -17.333%.
Which hedge fund is a major shareholder of Cue Biopharma?
Among the largest hedge funds holding Cue Biopharma’s share is Slate Path Capital LP. It holds Cue Biopharma’s shares valued at 2M.
---
Cue Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (134.38% Upside)
$3.00 (134.38% Upside)
Blogger Sentiment
Bullish
CUE Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $30.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-56.33%
12-Months-Change
Fundamentals
Return on Equity
-131.15%
Trailing 12-Months
Asset Growth
-34.95%
Trailing 12-Months
Company Description
Cue Biopharma
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
---
CUE Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.Read More>---
CUE Stock 12 Month Forecast
Average Price Target
$3.00
▲(134.38% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Cellectar Biosciences
―
Immunic
―
Meiragtx Holdings
―
Editas Medicine
―
Sangamo Biosciences
―
Best Analysts Covering CUE
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-16.48%
reiterated a buy rating 2 months ago
Copying Stephen Willey's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -16.48% per trade.
---